查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301013

美国虚拟临床试验市场规模、份额和趋势分析报告：按研究设计（干预、观察、扩展访问）、按适应症（癌症、心血管）、按阶段、按地区、按细分市场、2023-2030 年趋势

U.S. Virtual Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Indication (Oncology, Cardiovascular), By Phase, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国虚拟临床试验市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，到 2030 年，美国虚拟临床试验市场预计将达到 75.2 亿美元。

从 2023 年到 2030 年，该市场预计将以 5.45% 的复合年增长率增长。 远程医疗的采用、对患者多样性的需求以及临床试验中数据收集的加强以及医疗保健数字化的不断发展等因素是推动市场增长的因素。

在虚拟范式中，研究可以使用数字工具来加快招聘速度、减少管理费用并提高包容性。 例如，癌症中心开始使用人工智能 (AI) 将患者与临床试验相匹配。 这些平台从电子病历的结构化和非结构化部分收集患者数据，确定资格，并将患者与 ClinicalTrials.gov 数据库中适用的开放研究相匹配。 为此，我们使用自然语言处理和其他人工智能方法。

随着监管机构努力应对先前严格的资格要求的扩大，这些尖端分析工具在癌症中的重要性正在迅速增长。 这一因素为美国虚拟临床试验市场提供了利润丰厚的增长机会。 近年来，由于 COVID-19 大流行，远程医疗的使用量激增。 这是因为大多数研究资助者都是以患者为中心的。

临床试验中患者入组和保留的最大障碍之一是患者的地理位置和社会经济阶层。 这也可以通过远程医疗来解决，从而改善患者的多样性。 这为人群中的特定疾病以及研究药物对该人群的潜在影响提供了更真实的了解。 此外，在临床研究中使用远程医疗使患者不仅可以与研究人员更有效地互动，还可以与治疗医生更有效地互动。

疫情将研究从诊所转移到了家庭，迫使研究人员考虑新的数据收集方法。 FDA 已发布指令，暂时增加使用心电图仪和肺活量计等用于远程监测患者的非侵入性医疗设备的机会。 研究人员改变了评估频率，尤其是在肿瘤学领域。 这些进展符合虚拟试验方法，旨在衡量患者报告的结果并提高研究生成真实数据的能力。 受疫情影响，美国虚拟临床试验市场出现显着增长。

美国虚拟临床试验市场报告亮点

  • 由于针对各种疾病的新药开发进行的试验数量激增，介入试验设计领域将在 2022 年拥有最高的市场份额。
  • 扩大的准入领域潜力巨大，预计增长最快
  • 由于美国癌症患者数量增加，2022 年肿瘤领域将占据市场份额 57.73%
  • 由于该领域越来越多地采用虚拟临床试验，中枢神经系统领域将出现最大的增长。
  • 由于许多研究目前处于 II 期试验阶段，因此 II 期临床试验部分在 2022 年占据了最高的市场收入份额。
  • 随着许多临床试验在德克萨斯州和佛罗里达州等州进行，美国南部地区在美国市场占据主导地位，2022年的销售份额为33.25%。
  • 由于加利福尼亚州等专注于研究活动的州的存在，美国西部地区预计在预测期内增长最快。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 市场定义
  • 信息获取
    • 购买的数据库
    • GVR 内部数据库
    • 二手信息和第三方观点
    • 初步调查
    • 初步调查的详细信息
  • 信息分析
    • 数据分析模型
  • 市场形成和数据可视化
    • 产品流分析
  • 验证和发布数据
  • 全球市场：计算复合年增长率
  • 辅助信息列表
  • 主要信息列表

第 2 章执行摘要

  • 市场概况
  • 分段快照
  • 衝突注意事项概览

第三章市场变量、趋势和范围

  • 市场血统
    • 母公司市场分析
    • 补充市场分析
  • 美国虚拟临床试验市场 - 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 商业环境工具分析：美国虚拟临床试验市场
    • 波特五力分析
    • 杵分析
  • COVID-19 的影响分析

第 4 章美国虚拟临床试验市场：研究设计估算和趋势分析

  • 按研究设计划分的美国虚拟临床试验市场：主要要点
  • 美国虚拟临床试验市场：2022 年和 2030 年研究设计动态和市场份额分析
  • 介入治疗
    • 2018-2030 年干预市场估计和预测（十亿美元）
  • 观察性的
    • 2018-2030 年观察到的市场估算和预测（十亿美元）
  • 扩展访问权限
    • 2018-2030 年扩展接入市场估算和预测（十亿美元）

第 5 章美国虚拟临床试验市场：适应症估计和估计/趋势分析

  • 美国虚拟临床试验市场（按适应症）：主要要点
  • 美国虚拟临床试验市场：2022 年和 2030 年适应症趋势和市场份额分析
  • 肿瘤学
    • 2018-2030 年肿瘤市场估计和预测（十亿美元）
  • 心血管
    • 2018-2030 年心血管市场估计和预测（十亿美元）
  • 消化系统疾病
    • 2018-2030 年胃肠病学市场估计和预测（十亿美元）
  • 肌肉骨骼疾病
    • 2018-2030 年肌肉骨骼疾病市场估计和预测（十亿美元）
  • 感染
    • 2018-2030 年传染病市场估计和预测（十亿美元）
  • 中枢神经系统
    • 2018-2030 年中枢神经系统市场估计和预测（十亿美元）
  • 内分泌和代谢疾病
    • 2018-2030 年内分泌和代谢疾病市场估计和预测（十亿美元）
  • 其他
    • 2018-2030 年其他指标市场估计和预测（十亿美元）

第 6 章美国虚拟临床试验市场：阶段评估和趋势分析

  • 美国虚拟临床试验市场（按阶段）：主要要点
  • 美国虚拟临床试验市场：2022 年和 2030 年阶段转变和市场份额分析
  • 第一阶段
    • 2018-2030 年第一阶段市场估算和预测（十亿美元）
  • 第二阶段
    • 2018-2030 年第二阶段市场估算和预测（十亿美元）
  • 第三阶段
    • 2018-2030 年第三阶段市场估算和预测（十亿美元）
  • 第四阶段
    • 2018-2030 年第四阶段市场预估和预测（十亿美元）

第 7 章：美国虚拟临床试验市场：区域分析

  • 2022 年和 2030 年美国虚拟临床试验区域市场份额分析
    • 东北
    • 中西部
    • 南
    • 西

第 8 章竞争格局

  • 公司分类
  • 战略规划
  • 公司简介/列表
    • ICON, plc
    • Parexel International Corporation
    • IQVIA
    • Labcorp Drug Development
    • Medidata Solutions
    • Oracle
    • Signant Health
    • Medable, Inc.
    • Halo Health Systems
    • Science 37
Product Code: GVR-4-68040-085-3

U.S. Virtual Clinical Trials Market Growth & Trends

The U.S. virtual clinical trials market size is expected to reach USD 7.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.45% from 2023 to 2030. Factors such as the adoption of telehealth, the need for patient diversity clubbed with enhanced data collection in clinical trials, and the increasing digitalization in healthcare are factors driving the growth of the market.

In a virtual paradigm, researchers can use digital tools to speed up hiring, cut down on overheads, and increase inclusivity. For patient-trial matching, for instance, cancer centers are starting to use artificial intelligence (AI). These platforms collect patient data from both structured and unstructured parts of electronic medical records, determine eligibility, and match patients to pertinent open studies in the ClinicalTrials.gov database. They use natural language processing and other AI approaches for this purpose.

The importance of these cutting-edge analytics tools in cancer is rising rapidly, as regulators work to enlarge previously stringent eligibility requirements. This factor is representing lucrative growth opportunities for the virtual clinical trials market in the United States. As a result of the COVID-19 pandemic, telemedicine has seen a sharp increase in usage in recent years. This is because most of the sponsors funding research studies have placed a greater emphasis on patient-centricity.

One of the biggest obstacles to patient enrollment and retention in clinical trials is the patient's geographic location and/or socioeconomic class. This is addressed via telemedicine, which also improves the possibility of better patient diversity. This provides a more realistic picture of a certain illness in a population and the potential effects of an investigational drug on that population. Furthermore, patients can interact with researchers as well as the treating doctors more effectively, when telemedicine is used in clinical research.

The pandemic switched research attention from study clinics to homes, leading researchers to consider novel methods for data gathering. The FDA published instructions to temporarily increase access to noninvasive medical devices for remote patient monitoring, such as electrocardiographs and spirometers. Researchers have changed the assessment frequency specifically in oncology. These developments are compatible with the virtual trial approach, which aims to increase the ability of studies to gauge patient-reported outcomes and produce real-world data. The U.S. market for virtual clinical trials has observed notable growth due to the pandemic.

U.S. Virtual Clinical Trials Market Report Highlights

  • The interventional study design segment accounted for the highest market share in 2022 due to the rapid rise in the number of experiments being performed to develop novel medications for various diseases
  • The expanded access segment is anticipated to experience maximum growth as it represents great potential
  • The oncology segment dominated the market in 2022 with a revenue share of 57.73% owing to the rising cases of cancer in the United States
  • The CNS indication segment is expected to witness maximum growth due to the increasing adoption of virtual clinical trials in this area
  • The Phase II trials segment accounted for the highest revenue share in 2022 in the market due to many studies currently being under this study phase
  • The Southern region dominated the U.S. market in 2022 with a revenue share of 33.25%, owing to a significant number of clinical trials being carried out in states such as Texas and Florida
  • The Western region of the United States is anticipated to experience maximum growth during the forecast period, aided by the presence of states such as California that strongly focus on research activities

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
    • 1.5.1. Commodity Flow Analysis
      • 1.5.1.1. Approach 1: Commodity flow approach
      • 1.5.1.2. Approach 2: Country wise market estimation using bottom-up approach
  • 1.6. Data Validation & Publishing
  • 1.7. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segmental Snapshot
  • 2.3. Competitive Insights Snapshot

Chapter 3. Market Variables, Trends, and Scope

  • 3.1. Market Lineage
    • 3.1.1. Parent Market Analysis
    • 3.1.2. Ancillary Market Analysis
  • 3.2. U.S. Virtual Clinical Trials Market - Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. The increasing healthcare digitization
      • 3.2.1.2. The need for patient diversity clubbed with enhanced data collection in clinical trials
      • 3.2.1.3. Adoption of telehealth
      • 3.2.1.4. Alliances between biotechnology, pharmaceutical & clinical research organization
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data security
  • 3.3. Business Environmental Tools Analysis: U.S. Virtual Clinical Trials Market
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis
  • 3.4. COVID-19 Impact Analysis

Chapter 4. U.S. Virtual Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 4.1. U.S. Virtual Clinical Trials Market, By Study Design: Key Takeaways
  • 4.2. U.S. Virtual Clinical Trials Market: Study Design Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Interventional
    • 4.3.1. Interventional Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Observational
    • 4.4.1. Observational Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Expanded access
    • 4.5.1. Expanded Access Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Virtual Clinical Trials Market: Indication Estimates & Trend Analysis

  • 5.1. U.S. Virtual Clinical Trials Market, By Indication: Key Takeaways
  • 5.2. U.S. Virtual Clinical Trials Market: Indication Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Oncology
    • 5.3.1. Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Cardiovascular
    • 5.4.1. Cardiovascular Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. Digestive Diseases
    • 5.5.1. Digestive Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Musculoskeletal Diseases
    • 5.6.1. Musculoskeletal Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Infectious Diseases
    • 5.7.1. Infectious Diseases Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. CNS
    • 5.8.1. CNS Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Endocrinology & Metabolic Disease
    • 5.9.1. Endocrinology & Metabolic Disease Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. Others
    • 5.10.1. Other Indications Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Virtual Clinical Trials Market: Phase Estimates & Trend Analysis

  • 6.1. U.S. Virtual Clinical Trials Market, By Phase: Key Takeaways
  • 6.2. U.S. Virtual Clinical Trials Market: Phase Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Phase I
    • 6.3.1. Phase I Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Phase II
    • 6.4.1. Phase II Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Phase III
    • 6.5.1. Phase III Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Phase IV
    • 6.6.1. Phase IV Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Virtual Clinical Trials Market: Regional Analysis

  • 7.1. U.S. Virtual Clinical Trials Regional market share analysis, 2022 & 2030
    • 7.1.1. Northeast
      • 7.1.1.1. Northeast Market estimates and forecast, 2018 - 2030
    • 7.1.2. Midwest
      • 7.1.2.1. Midwest Market estimates and forecast, 2018 - 2030
    • 7.1.3. South
      • 7.1.3.1. South Market estimates and forecast, 2018 - 2030
    • 7.1.4. West
      • 7.1.4.1. West Market estimates and forecast, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. ICON, plc
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Service Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Parexel International Corporation
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Service Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. IQVIA
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Service Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Labcorp Drug Development
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Service Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Medidata Solutions
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Service Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Oracle
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Service Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Signant Health
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Service Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Medable, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Service Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Halo Health Systems
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Service Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Science 37
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Service Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Virtual Clinical Trials market, by study design, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Virtual Clinical Trials market, by indication, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Virtual Clinical Trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Virtual Clinical Trials market, by region, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 U.S. virtual clinical trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value - chain - based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 Related/ancillary market outlook
  • Fig. 14 U.S. Virtual Clinical Trials - Industry value chain analysis
  • Fig. 15 U.S. virtual clinical trials market driver analysis
  • Fig. 16 U.S. virtual clinical trials market restraint analysis
  • Fig. 17 U.S. virtual clinical trials market: Porter's Five Forces analysis
  • Fig. 18 U.S. virtual clinical trials market: PESTLE analysis
  • Fig. 19 U.S. virtual clinical trials market: Study design outlook and key takeaways
  • Fig. 20 U.S. virtual clinical trials market: Study design market share analysis, 2022 & 2030
  • Fig. 21 U.S. interventional study market, 2018 - 2030 (USD Billion)
  • Fig. 22 U.S. observational study market, 2018 - 2030 (USD Billion)
  • Fig. 23 U.S. expanded access study market, 2018 - 2030 (USD Billion)
  • Fig. 24 U.S. virtual clinical trials market: Indication outlook and key takeaways
  • Fig. 25 U.S. virtual clinical trials market: Indication market share analysis, 2022 & 2030
  • Fig. 26 U.S. oncology market, 2018 - 2030 (USD Billion)
  • Fig. 27 U.S. cardiovascular market, 2018 - 2030 (USD Billion)
  • Fig. 28 U.S. digestive diseases market, 2018 - 2030 (USD Billion)
  • Fig. 29 U.S. musculoskeletal diseases market, 2018 - 2030 (USD Billion)
  • Fig. 30 U.S. infectious diseases market, 2018 - 2030 (USD Billion)
  • Fig. 31 U.S. CNS market, 2018 - 2030 (USD Billion)
  • Fig. 32 U.S. endocrinology and metabolic diseases market, 2018 - 2030 (USD Billion)
  • Fig. 33 U.S. other indications market, 2018 - 2030 (USD Billion)
  • Fig. 34 U.S. virtual clinical trials market: Phase outlook and key takeaways
  • Fig. 35 U.S. virtual clinical trials market: Phase market share analysis, 2022 & 2030
  • Fig. 36 U.S. phase I virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 37 U.S. phase II virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 38 U.S. phase III virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 39 U.S. phase IV virtual clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 Northeast U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 42 Midwest U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 43 South U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 44 West U.S. virtual clinical trials market estimates and forecast, 2018 - 2030 (USD Billion)
  • Fig. 45 Key company categorization
  • Fig. 46 Company market positioning
  • Fig. 47 Market participant categorization
  • Fig. 48 Strategy framework